Display options
Cite
Sun Q, Shi J, Ren C, et al. Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria. Oncol Lett. 2020;19(6):4066-4076doi: 10.3892/ol.2020.11529.
Sun, Q., Shi, J., Ren, C., Du, Z., Shu, G., & Wang, Y. (2020). Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria. Oncology letters, 19(6), 4066-4076. https://doi.org/10.3892/ol.2020.11529
Sun, Quan, et al. "Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria." Oncology letters vol. 19,6 (2020): 4066-4076. doi: https://doi.org/10.3892/ol.2020.11529
Sun Q, Shi J, Ren C, Du Z, Shu G, Wang Y. Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria. Oncol Lett. 2020 Jun;19(6):4066-4076. doi: 10.3892/ol.2020.11529. Epub 2020 Apr 10. PMID: 32391107; PMCID: PMC7204632.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2020 Jun;19(6):4066-4076. doi: 10.3892/ol.2020.11529. Epub 2020 Apr 10.

Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria.

Oncology letters

Quan Sun, Jingxiang Shi, Chaoyi Ren, Zhi Du, Guiming Shu, Yijun Wang

Affiliations

  1. Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin 300170, P.R. China.
  2. Tianjin Key Laboratory of Artificial Cells, Tianjin 300170, P.R. China.
  3. Artificial Cell Engineering Technology Research Center of The Public Health Ministry, Tianjin 300170, P.R. China.
  4. Department of Hepatobiliary Surgery, Nankai University Affiliated Third Central Hospital, Tianjin 300170, P.R. China.
  5. Department of Hepatobiliary Surgery, The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, P.R. China.

PMID: 32391107 PMCID: PMC7204632 DOI: 10.3892/ol.2020.11529

Abstract

The aim of the present study was to compare the efficacy of microwave ablation (MWA) and surgical resection (RES) for the treatment of hepatocellular carcinoma (HCC) conforming to the Milan criteria and the associated short- and long-term survival rates. The baseline characteristics were obtained from 231 patients with HCC who met the Milan criteria. To compare the mortality rates between groups, survival analysis was conducted using the Kaplan-Meier method and the log-rank test. The factors associated with the survival rate were analyzed using Cox proportional hazard models. A total of 115 patients underwent RES, and 116 were treated with MWA. No significant differences were observed in the 1-, 3- and 5-year OS rates and the 1-year DFS rate between the two groups. The 7- and 10-year OS rates and the 3-, 5-, 7- and 10-year DFS rates of the RES group were significantly higher compared with those in the MWA group (P=0.004, P=0.002, P=0.003 and P=0.002, respectively). In addition, no marked differences were observed in the OS and DFS rates between the two groups of patients with solitary HCC lesions ≤3 cm (P=0.066 and P=0.056) and in the OS of those with solitary lesions of 3-5 cm (P=0.133); however the DFS of patients with single 3-5 cm HCC lesions in the RES group was notably higher compared with the MWA group (P=0.027). The Cox proportional hazard model revealed that age, hepatitis B and C virus infection, tumor size, number, platelet count and the type of treatment intervention were risk factors affecting the survival and recurrence in patients with HCC. These results suggested that RES may provide superior survival benefits compared with MWA for patients with HCC who meet the Milan criteria.

Copyright: © Sun et al.

Keywords: hepatocellular carcinoma; microwave ablation; surgical resection; survival analysis

References

  1. World J Hepatol. 2015 Nov 8;7(25):2578-89 - PubMed
  2. J Hepatol. 2017 Mar;66(3):545-551 - PubMed
  3. Gastroenterology. 2012 May;142(6):1264-1273.e1 - PubMed
  4. Eur Radiol. 2012 Sep;22(9):1983-90 - PubMed
  5. J Cancer Res Ther. 2018 Jan;14(1):40-45 - PubMed
  6. J Gastroenterol Hepatol. 2014;29(7):1500-7 - PubMed
  7. Hepatology. 2018 Feb;67(2):600-611 - PubMed
  8. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  9. World J Surg. 2004 Mar;28(3):258-62 - PubMed
  10. Ann Surg. 2009 Jan;249(1):20-5 - PubMed
  11. Gastroenterology. 2004 Nov;127(5 Suppl 1):S56-61 - PubMed
  12. Clin Cancer Res. 2014 Apr 15;20(8):2072-9 - PubMed
  13. Hepatogastroenterology. 2010 Jan-Feb;57(97):121-6 - PubMed
  14. Liver Int. 2016 Feb;36(2):284-92 - PubMed
  15. J Hepatol. 2012 Oct;57(4):794-802 - PubMed
  16. Chin J Cancer. 2013 Apr;32(4):162-9 - PubMed
  17. Pathol Oncol Res. 2018 Jul;24(3):663-670 - PubMed
  18. Hepatology. 2010 Jan;51(1):306 - PubMed
  19. Ann Gastroenterol. 2016 Oct-Dec;29(4):460-465 - PubMed
  20. J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S104-11 - PubMed
  21. Eur Rev Med Pharmacol Sci. 2017 Feb;21(3):523-529 - PubMed
  22. J Cancer Res Clin Oncol. 2013 May;139(5):773-81 - PubMed
  23. Semin Liver Dis. 2010 Feb;30(1):52-60 - PubMed
  24. Radiology. 2012 Mar;262(3):1022-33 - PubMed
  25. Ann Surg. 2006 Mar;243(3):321-8 - PubMed
  26. Radiology. 2005 Jul;236(1):132-9 - PubMed
  27. World J Surg. 2016 Jul;40(7):1709-19 - PubMed
  28. J Hepatol. 2018 Jul;69(1):182-236 - PubMed
  29. World J Gastroenterol. 2016 Nov 14;22(42):9279-9287 - PubMed
  30. Jpn J Clin Oncol. 2000 Mar;30(3):169 - PubMed
  31. Zhonghua Gan Zang Bing Za Zhi. 2017 Dec 20;25(12):886-895 - PubMed
  32. J Hepatol. 2012 Feb;56(2):412-8 - PubMed
  33. J Hepatol. 2013 Jul;59(1):89-97 - PubMed
  34. Radiology. 2005 Jun;235(3):728-39 - PubMed
  35. Hepat Oncol. 2017 Jul;4(3):83-98 - PubMed

Publication Types